Roche (RHHBY) expects an increase in Group sales in the mid single digit range. Core earnings per share are targeted to develop in the high single digit range. Roche expects to further increase its dividend in Swiss francs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Genentech announces INAVO120 study met key secondary endpoint
- Sarepta announces topline results from EMBARK study
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- Drugmakers to push Trump to pause price negotiations, Bloomberg reports
- Roche receives FDA clearance for B-cell lymphoma diagnostic test